Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

NCT06287398 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

DLBCL - Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
DLBCL, Nos Genetic Subtypes
High Grade B-Cell Lymphoma, Not Otherwise Specified
Follicular Large Cell Lymphoma, Relapsed
Follicular Large Cell Lymphoma

Interventions

DRUG: Epcoritamab

Sponsor

Australasian Leukaemia and Lymphoma Group